HbA2-Yokoshima (delta 25(B7)Gly >Asp) and Hb A2-Yialousa (delta 27(B9)Ala>Ser) in Turkey
Journal Title: Turkish Journal of Hematology - Year 2012, Vol 29, Issue 3
Abstract
To the Editor, Heterozygous beta-thalassemia (β-thal) carriers are characterized by microcytosis, hypochromia, and elevated HbA2 levels (≥3.5%) [1]. Although an elevated HbA2 level is a diagnostic parameter for b-thal, the interaction between d-globin gene mutation and b-thal can result in a normal HbA2 level, leading to misdiagnosis [2]. As δ-thalassemia(δ-thal) has no clinical significance, a reduced HbA2 level in β-thal carriers is an important parameter in the presence of d-thalassemia [3]. δ-globin gene mutations (http://globin.cse.psu.edu/hbvar/menu.html) have been reported [4]. HbA2-Yialousa (delta 27(B9)Ala>Ser) is the most common δ-thal mutation in the Mediterranean Region and was first identified by Trifillis et al. in a Sardinian family in 1991 [1,5]. HbA2-Yokoshima (delta 25(B7)Gly >Asp) was first identified in a Japanese family in which 1 member was homozygous [6].
Authors and Affiliations
Aylin Köseler, Ayfer Atalay, Erol Atalay
Keywords
Related Articles
- EP ID EP163408
- DOI 10.5505/tjh.2012.50470
- Views 66
- Downloads 0
Granülositik Sarkom (GS) Tedavisinde Megadoz Metilprednizolon (MDMP)
Sistinozis: Kemik İliği İncelemesinin Tanısal Rolü
Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia
Objective: Previous studies compared the predictive ability of the European Treatment Outcome Study (EUTOS), Sokal, and Hasford scoring systems and demonstrated inconsistent findings with unknown reasons. This study was...
EDTA-İlişkili Yalancı Trombositopeni
Otoimmun Hemolitik Anemili Bir Hastada Splenik İnfarkt